In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Zevra Therapeutics (ZVRA – Research Report), with a price target of $17.00. Jason Butler’s rating is based on a ...
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Zacks.com on MSN22h
Orbia Advance (MXCHY) Upgraded to Buy: Here's What You Should KnowOrbia Advance Corporation, S.A.B. de C.V. Unsponsored ADR (MXCHY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward ...
Cloudy. Medium chance of showers. The chance of a thunderstorm. Light winds. Sun protection recommended from 9:00 am to 4:40 pm, UV Index predicted to reach 9 [Very High] Partly cloudy. High chance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback